Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
It was previously shown that [18F]Fluorodopa (FDOPA) PET imaging results in intended
management changes in 41% of brain tumor patients. However, its impact on patient outcome
defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory
agencies require randomized trials to determine the impact of PET on patient management and
outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient
outcome by more accurately identifying presence or absence of tumor recurrence than
conventional imaging.
Phase:
Phase 1
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System